Reach Us +44-1904-929220
Targeting AMPK, MTOR And βCatenin By Combined Metformin And Aspirin Therapy In HCC: An Appraisal In Egyptian HCC Patients | 85139
ISSN: 1747-0862

Journal of Molecular and Genetic Medicine
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Targeting AMPK, mTOR and βCatenin by combined metformin and aspirin therapy in HCC: An appraisal in Egyptian HCC patients

Joint Meeting on 4th World Congress on Human Genetics & Genetic Diseases and 3rd International Conference on Molecular Medicine & Diagnostics

Doaa Ali Abdelmonsif, Ahmed S Sultan, Wessam F EL-Hadidy and Dina Mohamed Abdallah

Alexandria University, Egypt

ScientificTracks Abstracts: J Mol Genet Med

DOI: 10.4172/1747-0862-C1-024

Hepatocellular carcinoma (HCC) is an expanding health problem with a great impact on morbidity and mortality both in Egypt and worldwide. Recently, metformin and aspirin showed a potential anticancer effect on HCC although their mechanism(s) is not fully elucidated. To investigate the anti-proliferative effects of combined metformin/aspirin treatment against HCC, HepG2 cells were exposed to increasing concentrations of metformin, aspirin and combined treatment and MTT assay was performed. Caspase-3 activity, cell cycle analysis, protein expression of phosphorylated AMP-activated protein kinase (pAMPK) and mammalian target of rapamycin (mTOR) proteins were assessed. Furthermore, the expression and localization of β-catenin protein was assessed by immunocytochemistry (ICC). Finally, protein expression of pAMPK, mTOR and β-catenin was assayed in Egyptian HCC and cirrhotic tissue specimens. Results showed that metformin/aspirin combined treatment had a synergistic effect on cell cycle arrest and apoptosis induction via down-regulation of AMPK activation and mTOR protein expression. Additionally, metformin/aspirin combined treatment enhanced cell-cell membrane localization of β-catenin expression in HepG2 cells, which might inhibit metastatic potential of HepG2 cells. In Egyptian HCC specimens, pAMPK, mTOR and β-catenin proteins showed a significant expression compared to cirrhotic controls. In conclusion, combined metformin/aspirin treatment could be a promising therapeutic strategy for HCC and specifically Egyptian HCC patients.

Doaa Ali Abdelmonsif is an Assistant Professor of Medical Biochemistry, Faculty of Medicine, Alexandria University, Egypt. She also works as the Co-Manager of the Molecular Biology Laboratory, Centre of Excellence for Regenerative Medicine Research & Applications (CERRMA), Alexandria University and a Research Associate of the Nanomedicine Laboratory, CERRMA. She has completed her MD on pharmaco-genetic and epigenetic studies in breast cancer. Her research interest is in the fields of molecular biology, nanomedicine and cell therapy. She also serves as a Reviewer for many peer-reviewed specialized journals and a member of molecular biology, oncology and nanomedicine societies.
Email:[email protected]

Relevant Topics